Article | September 14, 2023

Moving The Needle: Continuous Processing For Enhanced Monoclonal Antibody Production

Source: Cytiva
Scientist Laboratory sample pipette GettyImages-1354172647

Although therapeutic monoclonal antibodies (mAbs) have been around for over 25 years, production of these essential biologics has only recently started to transition from traditional methods to advanced bioprocessing techniques. Newer bioprocessing technologies, such as continuous processing, have demonstrated the ability to increase production speeds while reducing costs.

In a recent webinar titled "Monoclonal Antibodies and Continuous Processing: A Case Study Examination," experts from Cytiva and Chugai Pharmaceutical, a Roche company, discussed their unique collaboration for the continuous processing of mAbs. The partnership led to the successful implementation of a semi-continuous pilot processing line, which enabled increased productivity and a smaller footprint.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development